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Osteosarcoma (OS) responds poorly to radiotherapy, but the mechanism is unclear. We found OS tumor
tissues expressed high level of protein HIF-1α, a common biological marker indicative of hypoxia. It is
known that hypoxic cells are generally radioresistant because of reduced production of irradiation-in-
duced DNA-damaging reactive oxygen species (ROS) in the anaerobic condition. Here we report another
mechanism how hypoxia induces radioresistance. In MG-63 human osteosarcoma cells, hypoxic pre-
treatment increased the cellular survival in irradiation. These hypoxia-exposed cells displayed com-
partmental recruitment of GFP-tagged LC3 and expression of protein LC3-II, and restored the radio-
sensitivity upon autophagy inhibition. The following immunohistochemistry of OS tumor tissue sections
revealed upregulated LC3 expression in a correlation with HIF-1α protein level, implying the possibly
causative link between hypoxia and autophagy. Further studies in MG-63 cells demonstrated hypoxic
pretreatment reduced cellular and mitochondrial ROS production during irradiation, while inhibition of
autophagy re-elicited them. Taken together, our study suggests hypoxia can confer cells resistance to
irradiation through activated autophagy to accelerate the clearance of cellular ROS products. This might
exist in human osteosarcoma as an additional mechanism for radioresistance.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteosarcoma (OS) is the most common type of primary bone
cancer that mainly affects younger populations [1,2]. Current
therapies combining surgery with chemotherapy (doxorubicin and
cisplatin with or without methotrexate) yield 60–70% of the 5-year
survival rate. However, the effective cure for patients with meta-
static or relapsed osteosarcoma is still challenging [3]. Therefore,
improvement of the existing therapies and exploitation of other
approaches are highly anticipated.
Radiotherapy is an alternative combinatory therapy for OS. The
incorporation of radiotherapy signiﬁcantly improved the efﬁciency
of chemotherapy by certain anticancer drugs (e.g., ifosfamide,
cisplatin, HDMTX, etc.) [4], which even led to a long-termGmbH. This is an open access art
alpha; ROS, reactive oxygen
, microtubule-associated
thyladenine
).remission in some patients [5]. Locally complete cure could also be
observed in unresectable or partially resected cases by radio-
therapy when applied at high intensity [6]. Nevertheless, OS is
generally considered radioresistant with poorly understood me-
chanism [7].
In this study, we found HIF-1α was overexpressed in human OS
tissues. HIF proteins are often indicators of hypoxia which is
common in solid tumors like OS where blood supply in the mi-
croenvironment is usually limited [8–11]. In cancer stem cells, HIF
proteins promote tumor aggressiveness and confer resistance to
certain therapies including irradiation [12–15].
The mechanism that tumor with hypoxia has reduced sensitive
to radiotherapy is well studied [16]. It is known that irradiation
generates free radicals on DNA. At the normal condition, these
radicals can be ﬁxed by oxygen (O2) to generate DNA-damaging
ROS products which will initiate cellular death. However, this
death-inducing effect is compromised when the oxygen avail-
ability is low in hypoxic cells and ROS production is therefore
limited [17].
Here, we found an additional mechanism that involvesicle under the CC BY-NC-ND license
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dependent of oxygen at the time during irradiation. Autophagy is a
process in which subcellular organelles or complex of proteins are
sequestrated by intracellular membranes and then fused with ly-
sosomes for degradation. This process is an important to eliminate
damaged cellular components and maintain cellular survival [18].
Autophagy has been evidenced to be involved in cancer [19–21],
and recent studies suggest its contribution to radioresistance in
various tumors. Lomonaco et al. have found the induction of au-
tophagy contributes to the radioresistance of glioma stem cells
[22]. The Rodemann group also reported that autophagy also
caused resistance to ionizing radiation in breast cancer cell lines
[23]. The similar phenomenon was additionally evidenced in
pancreatic cancer cells [24]. Another study also thoroughly sup-
port the role of autophagy in mediating radioresistance [25].
In this study, we propose that autophagy induced by hypoxia is
another important mechanism that accounts for the radio-
resistance of OS.2. Materials and methods
2.1. Patient samples
Histopathologically conﬁrmed parafﬁn-embedded tissue sec-
tions from 89 osteosarcoma (51 males and 38 females) and 28 age-
matched osteochondroma patients (16 males and 12 females)
were recruited from the Fourth Hospital of Hebei Medical Uni-
versity. Clinical stages were evaluated according to the 2002
American Joint Committee on Cancer (AJCC). This study complied
with the Declaration of Helsinki and was approved by the Human
Ethics and Research Ethics Committees of the hospital. Written
informed consents were obtained from all patients.
2.2. Tissue section and cell immunostaining
Parafﬁn-embedded tissue sections (4 mm) were incubated se-
quentially with primary antibodies and HRP-conjugated secondary
antibodies. The signal was developed by EnVisionTM Peroxidase/
DAB detection kit (Dako, UK). For immunocytochemical staining,
MG-63 cells were washed with PBS and then received common
processes like ﬁxation (4% paraformaldehyde), permeabilization,
blocking, and antibody incubation. Antibodies used in this study
included anti-HIF-1α (Abcam, USA), anti-LC3 (Novus Biologicals,
USA) and anti-γH2AX (Cell Signaling, USA). DAPI, Hoechst 33,258
and dichloroﬂuorescin diacetate (DCF-DA) were purchased from
Sigma-Aldrich of USA. MitoSOX Red was from Thermo Fisher Sci-
entiﬁc of USA.
2.3. Cell culture and irradiation procedure
Human MG-63 osteosarcoma cells were cultured in the DMEM
medium (10% FBS, 50 U/ml penicillin, 50 μg/ml gentamicin, 2.5 mg/
ml amphotericin B, 1% glutamine and 2% HEPES) at 37 °C in at-
mosphere with 5% CO2. ELEKTA Synergy Linear Accelerator (Cra-
voley, UK) was used to treat the cells at 6 Gy (350 cGy/min) unless
otherwise indicated. Culture medium was replaced with fresh
medium without serum or antibiotics at 6 h before irradiation.
Cellular viability was measured by the trypan blue exclusion
method.
2.4. Western blot
Cell lysate with equal amount of protein was resolved by SDS-
PAGE, and then transferred to NC membrane. After being blocked
by 5% nonfat milk, the membrane was incubated with primary andsecondary antibodies sequentially. Signals were developed by Pico
Chemiluminescent Substrate (Thermo Fisher Scientiﬁc, USA) on
ﬁlms.
2.5. Statistical analysis
ANOVA, Tukey's test, and regression analysis were performed
by software SPSS 21.0.3. Results
3.1. HIF-1α expression is increased in osteosarcoma and is asso-
ciated with the survival rate
It is established that hypoxia is common in most solid tumors
due to limited blood supply in the microenvironment. This low
oxygen condition and cellular adaptive responses often cause tu-
mor aggressiveness and resistance to treatments including irra-
diation. Osteosarcoma (OS) is commonly known to be radio-
resistant. To determine whether radioresistance of this solid tumor
could possibly involve hypoxia, we recruited osteosarcoma tissues
from 89 cases to stain the typical hypoxia marker, HIF-1α, by
immunohistochemistry, using 28 control samples from os-
teochondroma (OC), the most common benign bone tumor.
When compared to OC controls, most OS tissue samples ex-
pressed higher level of HIF-1α. Much more cells demonstrated
positive staining and had stronger intensity in OS sections
(Fig. 1A). Because the staining intensity was largely correlated with
the number of positively stained cells, we simply counted the
number of cells with observable staining and calculated the per-
centage of HIF-1α positive cells to grade the expression level
ranges. 5%, 15% and 45% were used as the cutoff values for ex-
pression ranges of ““, “þ”, “þþ” and “þþþ”accordingly. We
found 82 out of 89 (92.1%) OS sections expressing HIF-1α in po-
sitive ranges [“þ”: 16 (18.0%); “þþ”: 25 (28.1%); and “þþþ”: 41
(46.1%)] (Fig. 1B). In contrast, most OC samples have no or rela-
tively low HIF1α expression [““: 23 (82.1%); “þ”: 5(17.9%)].
HIF-1α expression in cancer often results from hypoxia and
predicts poor prognosis because it is involved in tumor aggres-
siveness and intractability such as chemoresistance, radio-
resistance, angiogenesis, vasculogenesis, invasiveness and metas-
tasis [9,26]. We therefore looked into the case medical history
records and found the overall survival rate of these patients was
correlated with HIF-1α expression: cases in the “þþþ” range had
signiﬁcantly lower survival rate than those in the “ or þ”, “þþ”
ranges (Fig. 1C, Kaplan-Meier curve, the log rank test, p¼0.019).
“The positive correlation of HIF-1α expression with the post-
operative treatment (mainly chemotherapy) indicates HIF-1α ex-
pressed in the tumor tissue exerts a biological effect. Because HIF-
1α can contribute to resistance of both chemotherapy and irra-
diation [9,17,27,28], therefore although none of these patients
received irradiation after surgery, the poorer chemotherapeutic
efﬁciency on patients with higher HIF-1α expression might im-
plicate a insensitive response of these cases to irradiation as well”.
3.2. Hypoxia pretreatment protects osteosarcoma cells from
irradiation
It is commonly known that hypoxic cells generally are less
sensitive to irradiation because of insufﬁcient oxygen to generate
toxic ROS. We found another mechanism how hypoxia leads to
radioresistance in a cellular model. This mechanism requires hy-
poxia not during the irradiation, but prior to the irradiation.
The human osteosarcoma cell line MG-63 was used to de-
monstrate in this study. We ﬁrst determined the optimal
Fig. 1. HIF-1α expression in osteosarcoma tissues and association with survival rate after surgical resection. (A) HIF-1α protein expression by immunohistochemistry in
osteochondroma (OC) and osteosarcoma (OS) tumor tissues. (B) Summary of HIF-1α expression in OS and OC tissues. Expression level is graded based on the percentage of
positively stained cells. “”:o5%; “þ”: 5–15%; “þþ”: 15–45%; “þþþ”:445%. For each sample section, 5 view ﬁelds under the microscope were chosen. Three were from
the region with the average number of total cells, and two other were from the densest or sparsest region respectively. (C) The overall survival rate of OS patients with
different HIF-1a expression range. Kaplan-Meier curve, the log rank test, p¼0.019.
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the one that caused nearly 50% cellular death is 5.6 Gy (Fig. 2A).
We therefore chose 6 Gy in this study. DNA damage was veriﬁed in
cells receiving irradiation at this dose by immunocytochemical
staining of gamma-H2AX (Fig. 2B). Besides, we also conﬁrmed on
the Western blot that 1% O2, the typical experimental condition to
induce hypoxia, elicited the expression of HIF-1α (Fig. 2C), in-
dicating the successful induction of cellular hypoxic response un-
der this oxygen condition.
When preincubated in 1% O2 for 24 h, cells showed reduced
death by irradiation as compared to those without hypoxic pre-
treatment under the microscope (Fig. 2D). Overall, the cell survival
rate evaluated by the trypan blue exclusion method was 46.5%
under the irradiation, but increased to 72.4% signiﬁcantly by hy-
poxic exposure prior to irradiation (Fig. 2E), suggesting hypoxic
pretreatment introduced cellular tolerance to irradiation.
3.3. Hypoxic treatment induces autophagy in MG-63 cells
Autophagy regulates tumorigenesis and is involved in radio-
resistance in cancer therapy [21,29,30]. Autophagy can also be
induced by hypoxia, which in turn contributes to the reduced
sensitivity to therapeutic irradiation [28,31,32]. We ﬁrst examined
whether autophagy could similarly be activated in osteosarcoma
cells by hypoxia by expressing GFP tagged protein LC3 in MG-63cells to trace the morphological change of autophagy. LC3, the
Microtubule-associated protein 1 A/1B-light chain 3, is a common
marker for autophagic activation [33]. When autophagy begins,
the cytosolic form of LC3 (LC3-I) is conjugated to phosphatidy-
lethanolamine to become LC3-phosphatidylethanolamine con-
jugate (LC3-II), which is recruited to autophagosomal membranes.
Detection of LC3 by immunoblotting or immunoﬂuorescence is
generally considered a reliable method for monitoring autophagy
and autophagy-related processes.
Under 1% O2 treatment for 24 h, the green signals were re-
cruited from even distribution to localized speckles that resembled
typical sequestering compartments during autophagosome for-
mation (Fig. 2F). The Western blot also demonstrated the expres-
sion of LC3-II, the featured modiﬁcation of LC3 required for au-
tophagosome maturation (Fig. 2G). These suggest hypoxic treat-
ment is able to induce the activation of autophagy in osteosarcoma
cells.
To determine whether this hypoxia induced autophagy was
possibly involved in reduced cellular sensitivity to irradiation, we
added two different autophagy inhibitors, 10 μM chloroquine (CQ)
and 2 mM 3-methyladenine (3-MA), into the cell culture medium
2 h before the irradiation. Without treatments, the survival rate
under irradiation with the pretreatment of 1% O2 was 75.1%.
However, this was reduced to 52.5% and 49.6% by CQ and 3-MA
respectively, which was close to the 48.3% under irradiation when
Fig. 2. Hypoxia pretreatment mediates radioresistance and induces autophagy in osteosarcoma cells. (A) MG-63 cell death rate by irradiation at different dosages. The
dosage that causes 50% of cell death is about 5.6 Gy. (B) Immunoﬂuorescence of gamma-H2AX indicates DNA damage induced by irradiation in MG-63 cells. (C) Western blot
to demonstrate HIF-1α induction by the hypoxic treatment. (D) Reduced cellular death from irradiation by hypoxic pretreatment. (E) Trypan Blue staining to assess the
cellular survival at different irradiation and hypoxic conditions. Error bar is standard deviation; one-way ANOVA (po0.05) and Tukey's tests were used (both *po0.05).
(F) Morphological change of MG-63 cells expressing GFP-tagged LC3 in hypoxic treatment (1% O2) for 24 h. (G) Activated autophagy of MG-63 cells in hypoxia as assessed by
LC3-II. (H) Autophagy inhibition abolishes protective effect of hypoxic pretreatment. CQ: Chloroquine, 10 μM; 3-MA: 3-methyladenine, 2 mM. Error bar is S.D.; one-way
ANOVA (po0.05) followed by Tukey's tests (*po0.05 and both **po0.05).
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notable that these two drugs did not show signiﬁcant toxic effect
on the cells in this experiment.
Taken together, these results suggest the hypoxia can induce
autophagy to protect cells from irradiation, implying a possible
novel mechanism of radioresistance in human osteosarcoma.
3.4. LC3 expression is correlated with HIF-1α in osteosarcoma
tissues
To examine whether the activated autophagy also exists in the
osteosarcoma tissues, we stained the protein LC3 by im-
munohistochemistry. Tissue sections from 15 OS cases with dif-
ferent HIF-1α expression in “þ“, “þþ” or “þþþ” ranges were
selected. LC3 staining was generally stronger in samples expres-
sing higher HIF-1α (Fig. 3A), indicating an upregulated autophagicactivation in these tissues. If autophagy is induced by hypoxia,
then presumably there is a correlation between LC3 and HIF-1α
expressions. Indeed, their relative abundances derived from their
immunostainings have demonstrated a correlation of “R2¼0.4407”
with a signiﬁcance in the regression analysis (p¼0.0070) (Fig. 3B).
These results imply that the hypoxia in the osteosarcoma tissues
have probably activated the autophagy.
3.5. Hypoxia-induced autophagy reduces ROS production during
irradiation
The ionizing radiation used in radiotherapy kills cells through
ROS [17]. The irradiation introduced radicals on the DNA (DNA) are
ﬁxed by O2 to form superoxide which causes DNA double-strand
breaks to initiate the cellular death processes. Therefore, ROS
production is the key event in the mechanism of radiotherapy.
Fig. 3. Elevated autophagy in osteosarcoma. (A) Immunohistochemistry of HIF-1α and LC3-II in osteosarcoma tissues from two different cases that express high or low
protein level of HIF-1α. (B) HIF-1α expression correlates with LC3-II in osteosarcoma tissues. Tissue sections from 15 OS cases with different HIF-1α expression levels were
selected. LC3 relative abundance was calculated as follows. Multiple images (up to 10) were initially taken from different regions that contained dense, average or sparse
cells. One image from each of the three ranges that had similar cell number among all 15 samples were ﬁnally chosen: 15 images in each range with no more than 50%
difference in cell number, 45 images in total. The overall staining intensity (mixed nuclear and LC3 signals) was quantiﬁed by the software Image J from multiple areas
(http://imagej.nih.gov/ij/), and then averaged and normalized to the cell number. Three images for each case were further averaged, and the ﬁnal value was considered the
abundance of LC3 of this case. The case with the highest LC3 abundance was considered 100%, and all other 14 cases were normalized to this case to have “relative
abundance” result values which were used in this correlation curve. The percentage of stained cells was used for HIF-1α expression abundance, and the highest expression
was used for normalization to yield “relative abundance”. Regression analysis, p¼0.0070.
Fig. 4. Hypoxia-induced autophagy reduces irradiation-induced ROS production. (A-G): DNA damage indicated by immunestaining of gamma-H2AX and DAPI. Cellular ROS
generation (H-N) and mitochondrial ROS generation (O-U) under different treatments by dichloroﬂuorescin diacetate (DCF-DA) staining and MitoSOX Red respectively. MG-
63 Cells received treatments as indicated in the ﬁgures and ﬁxed for immunestaining at 6 h- after irradiation. CQ, 10 μM; 3-MA, 2 mM. The scale bars for the top (A-G),
middle (H-N) and bottom (O-U) layers are 10 mm, 50 mm and 5 mm respectively.
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mediated protective effect on cellular death upon irradiation, we
examined the cellular and mitochondrial ROS production in MG-
63 cells during irradiation under different treatments using gam-
ma-H2AX (DNA double-strand maker), dichloroﬂuorescin diace-
tate (cellular ROS marker) and MitoSOX Red (mitochondrial ROS
marker). As expected, cells displayed DNA damage and increasedboth cellular and mitochondrial ROS by irradiation (Fig. 4A–D, H–K
and O–R); and these alterations were restored by the pretreatment
of 24 h' incubation in 1% O2 prior to irradiation (Fig. 4E, L and S).
However, this protective effect was abolished by both autophagy
inhibitors (10 μM CQ and 2 mM 3-MA), as the DNA damage and
both cytoplasmic and mitochondrial ROS products reappeared
(Fig. 4F-G, M-N and T-U). These observations suggest that the
H. Feng et al. / Journal of Bone Oncology 5 (2016) 67–7372cellular radioresistance medicated by hypoxia-induced autophagy
is probably through accelerated clearance of ROS products during
irradiation.4. Discussion
In this study, we found HIF-1α overexpression and possibly
hypoxia-induced autophagic activation in human osteosarcoma
tissues. Hypoxic cells are known to be less sensitive to radio-
therapy because of reduced generation of DNA-damaging ROS
during irradiation when low oxygen is present. In addition to this
common mechanism, we have found hypoxia confers radio-
resistance by inducing autophagy which can accelerate scavenging
toxic ROS products. Both of these mechanisms are probably in-
volved in the radioresistance of human osteosarcoma tissues.
Insights from studies on cancer stem cells which often de-
monstrate resistance to irradiation include: 1) prolonged S-phase
in cell cycle or more population of cells in this phase as mitotic
cells are more sensitive to irradiation; 2) increased DNA repair
activity; 3) enhanced ROS scavenging capacity and upregulated
HIF-1α; and 4) rescuing cues from stromal environment [12]. Here
it is very clear that accelerated ROS clearance and activated hy-
poxic response are among common mechanisms for radio-
resistance. We have found in this study that both of these are
present in the human osteosarcoma, although other mechanism
mentioned here might be existent as well.
It is established that hypoxia can induce autophagy [32,34–37].
We evidenced the autophagic activation in the cultured human
osteosarcoma MG-63 cells after incubation in 1% O2 for 24 h. The
concomitantly elevated LC3 protein levels with HIF-1α high ex-
pression on OS tissue sections also indicates hypoxia might have
activated autophagy in human OS tissues.
A recent publication also supports our study [38]. This report
demonstrated that irradiation induced ROS accumulation which
led to DNA damage in mesenchymal stem cells. However, this toxic
effect was reduced by autophagic induction, supporting the notion
that autophagy has an important role in conferring cells the tol-
erance to irradiation. Consistently, the hypoxia-induced autophagy
has also been evidence in other radioresistant cancers [23,28,39].
How autophagy is activated in OS needs be further studied.
Proteins and pathways like HIF-1α, BNIP3, MAP1LC3B, ATG5, ATF4,
AMPK, etc., have been reported to have mechanistic roles in hy-
poxia-induced autophagic activation [32,40–44]. The recent ad-
vancement of next generation sequencing technologies might re-
veal more speciﬁc clues by comprehensive analyses of the entire
molecular proﬁles from the clinical OS tissues with proper controls
[45–50].
In summary, we have found hypoxia-induced autophagy might
contribute to radioresistance in osteosarcoma as an additional
mechanism. Therefore, the pharmacological inhibition of autop-
hagy might improve the efﬁciency of radiotherapy in human os-
teosarcoma treatments.Conﬂict of interest
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